Cargando…

Persistence of Babesia microti Infection in Humans

Persistent infection is a characteristic feature of babesiosis, a worldwide, emerging tick-borne disease caused by members of the genus Babesia. Persistence of Babesia infection in reservoir hosts increases the probability of survival and transmission of these pathogens. Laboratory tools to detect B...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloch, Evan M., Kumar, Sanjai, Krause, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789900/
https://www.ncbi.nlm.nih.gov/pubmed/31319461
http://dx.doi.org/10.3390/pathogens8030102
_version_ 1783458720216252416
author Bloch, Evan M.
Kumar, Sanjai
Krause, Peter J.
author_facet Bloch, Evan M.
Kumar, Sanjai
Krause, Peter J.
author_sort Bloch, Evan M.
collection PubMed
description Persistent infection is a characteristic feature of babesiosis, a worldwide, emerging tick-borne disease caused by members of the genus Babesia. Persistence of Babesia infection in reservoir hosts increases the probability of survival and transmission of these pathogens. Laboratory tools to detect Babesia in red blood cells include microscopic detection using peripheral blood smears, nucleic acid detection (polymerase chain reaction and transcription mediated amplification), antigen detection, and antibody detection. Babesia microti, the major cause of human babesiosis, can asymptomatically infect immunocompetent individuals for up to two years. Chronically infected blood donors may transmit the pathogen to another person through blood transfusion. Transfusion-transmitted babesiosis causes severe complications and death in about a fifth of cases. Immunocompromised patients, including those with asplenia, HIV/AIDS, malignancy, or on immunosuppressive drugs, often experience severe disease that may relapse up to two years later despite anti-Babesia therapy. Persistent Babesia infection is promoted by Babesia immune evasive strategies and impaired host immune mechanisms. The health burden of persistent and recrudescent babesiosis can be minimized by development of novel therapeutic measures, such as new anti-parasitic drugs or drug combinations, improved anti-parasitic drug duration strategies, or immunoglobulin preparations; and novel preventive approaches, including early detection methods, tick-avoidance, and blood donor screening.
format Online
Article
Text
id pubmed-6789900
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67899002019-10-16 Persistence of Babesia microti Infection in Humans Bloch, Evan M. Kumar, Sanjai Krause, Peter J. Pathogens Review Persistent infection is a characteristic feature of babesiosis, a worldwide, emerging tick-borne disease caused by members of the genus Babesia. Persistence of Babesia infection in reservoir hosts increases the probability of survival and transmission of these pathogens. Laboratory tools to detect Babesia in red blood cells include microscopic detection using peripheral blood smears, nucleic acid detection (polymerase chain reaction and transcription mediated amplification), antigen detection, and antibody detection. Babesia microti, the major cause of human babesiosis, can asymptomatically infect immunocompetent individuals for up to two years. Chronically infected blood donors may transmit the pathogen to another person through blood transfusion. Transfusion-transmitted babesiosis causes severe complications and death in about a fifth of cases. Immunocompromised patients, including those with asplenia, HIV/AIDS, malignancy, or on immunosuppressive drugs, often experience severe disease that may relapse up to two years later despite anti-Babesia therapy. Persistent Babesia infection is promoted by Babesia immune evasive strategies and impaired host immune mechanisms. The health burden of persistent and recrudescent babesiosis can be minimized by development of novel therapeutic measures, such as new anti-parasitic drugs or drug combinations, improved anti-parasitic drug duration strategies, or immunoglobulin preparations; and novel preventive approaches, including early detection methods, tick-avoidance, and blood donor screening. MDPI 2019-07-17 /pmc/articles/PMC6789900/ /pubmed/31319461 http://dx.doi.org/10.3390/pathogens8030102 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bloch, Evan M.
Kumar, Sanjai
Krause, Peter J.
Persistence of Babesia microti Infection in Humans
title Persistence of Babesia microti Infection in Humans
title_full Persistence of Babesia microti Infection in Humans
title_fullStr Persistence of Babesia microti Infection in Humans
title_full_unstemmed Persistence of Babesia microti Infection in Humans
title_short Persistence of Babesia microti Infection in Humans
title_sort persistence of babesia microti infection in humans
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789900/
https://www.ncbi.nlm.nih.gov/pubmed/31319461
http://dx.doi.org/10.3390/pathogens8030102
work_keys_str_mv AT blochevanm persistenceofbabesiamicrotiinfectioninhumans
AT kumarsanjai persistenceofbabesiamicrotiinfectioninhumans
AT krausepeterj persistenceofbabesiamicrotiinfectioninhumans